title: Characterization of PCS1055, a novel muscarinic M4 receptor antagonist.
abstract: Identification of synthetic ligands selective for muscarinic receptor subtypes has been challenging due to the high sequence identity and structural homology among the five muscarinic acetylcholine receptors. Here, we report the pharmacological characterization of PCS1055, a novel muscarinic M4 receptor antagonist. PCS1055 inhibited radioligand [(3)H]-NMS binding to the M4 receptor with a Ki=6.5nM. Though the potency of PCS1055 is lower than that of pan-muscarinic antagonist atropine, it has better subtype selectivity over previously reported M4-selective reagents such as the muscarinic-peptide toxins (Karlsson et al., 1994; Santiago and Potter, 2001a) at the M1 subtype, and benzoxazine ligand PD102807 at the M3-subtype (Bohme et al., 2002). A detailed head-to-head comparison study using [(3)H]-NMS competitive binding assays characterizes the selectivity profiles of PCS1055 to that of other potent muscarinic-antagonist compounds PD102807, tropicamide, AF-DX-384, pirenzapine, and atropine. In addition to binding studies, the subtype specificity of PCS1055 is also demonstrated by functional receptor activation as readout by GTP-γ-[(35)S] binding. These GTP-γ-[(35)S] binding studies showed that PCS1055 exhibited 255-, 69.1-, 342- and >1000-fold greater inhibition of Oxo-M activity at the M4 versus the M1-, M2(-), M3-or M5 receptor subtypes, respectively. Schild analyses indicates that PCS1055 acts as a competitive antagonist to muscarinic M4 receptor, and confirms the affinity of the ligand to be low nanomolar, Kb=5.72nM. Therefore, PCS1055 represents a new M4-preferring antagonist that may be useful in elucidating the roles of M4 receptor signaling.
authors.affiliation: Lilly Research Laboratories, Neuroscience Division, Indianapolis, IN, U.S.A.
authors.forename: Carrie H
authors.initials: CH
authors.lastname: Croy
authors.affiliation: Neuroscience Discovery Research, Lilly Research Centre, Surrey, United Kingdom.
authors.forename: Wai Y
authors.initials: WY
authors.lastname: Chan
authors.affiliation: Lilly Research Laboratories, Neuroscience Division, Indianapolis, IN, U.S.A.
authors.forename: Andrea M
authors.initials: AM
authors.lastname: Castetter
authors.affiliation: Lilly Research Laboratories, Neuroscience Division, Indianapolis, IN, U.S.A.
authors.forename: Marla L
authors.initials: ML
authors.lastname: Watt
authors.affiliation: Lilly Research Laboratories, Neuroscience Division, Indianapolis, IN, U.S.A.
authors.forename: Anne T
authors.initials: AT
authors.lastname: Quets
authors.affiliation: Lilly Research Laboratories, Neuroscience Division, Indianapolis, IN, U.S.A. Electronic address: Felder@lilly.com.
authors.forename: Christian C
authors.initials: CC
authors.lastname: Felder
mesh_terms: D000818:Animals; D001667:Binding, Competitive; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D006575:Heterocyclic Compounds, 3-Ring / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008297:Male; D051379:Mice; D018727:Muscarinic Antagonists / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D011724:Pyridazines / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D043588:Receptor, Muscarinic M4 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013379:Substrate Specificity
chemical_list: D006575:Heterocyclic Compounds, 3-Ring; D018727:Muscarinic Antagonists; C000614592:PCS1055; D011724:Pyridazines; D043588:Receptor, Muscarinic M4
keywords: Competitive antagonists; Muscarinic M(4) receptors; PCS1055; Subtype selectivity